Showing results (131-140 of 1,983) with videos related to

Sort By:
Pageof 199
Thoracic Cancer|June 13, 2018
Phase I safety and pharmacokinetic study of cipatinib, an original dual tyrosine kinase inhibitorJiayu Wang, Yiqun Han, Xiuqing Shi, et al.
Cancer Communications (London, England)|December 6, 2018
The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world studyBinliang Liu, Tao An, Meiying Li, et al.
Signal Transduction and Targeted Therapy|July 7, 2021
The molecular tumor burden index as a response evaluation criterion in breast cancerZongbi Yi, Fei Ma, Guohua Rong, et al.
Therapeutic Advances in Medical Oncology|October 16, 2023
Eribulin combined with antiangiogenic agents in women with HER2-negative metastatic breast cancer: a retrospective multicenter studyMingxia Jiang, Bin Shao, Donggui Wan, et al.
Cancer Letters|February 20, 2026
Spatially Resolved Transcriptomics Identifies Tumor-Stroma-Immune Networks and Therapeutic Targets in Endocrine-Resistant Advanced Breast Cancer Treated with Everolimus+Letrozole: Insights from the MIRACLE TrialXuemin Xue, Danyang Ji, Liyan Xue, et al.
Therapeutic Advances in Medical Oncology|November 18, 2024
Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: a multicenter real-world studyYujing Tan, Zexi Peng, Hanfang Jiang, et al.
Oncotarget|July 23, 2016
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trialPin Zhang, Yi Yin, Hongnan Mo, et al.
Thoracic Cancer|September 16, 2024
Subdivision of M1 category and prognostic stage for de novo metastatic breast cancer to enhance prognostic prediction and guide the selection of locoregional therapyLei Ji, Ge Song, Min Xiao, et al.
International Journal of Cancer|July 7, 2018
Toremifene, rather than tamoxifen, might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in ChinaBo Lan, Fei Ma, Shanshan Chen, et al.
Breast (Edinburgh, Scotland)|September 4, 2024
Major pathologic response and long-term clinical benefit in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer after neoadjuvant chemotherapyLei Ji, Xi Chen, Xiaoyan Qian, et al.
Pageof 199